Efficacy of Pegylated interferon treatment for chronic hepatitis B

Efficacy of Pegylated interferon treatment for chronic hepatitis B - Efficacy of Pegylated interferon

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018371

Enrollment

100

Registered

2015-08-01

Start date

2015-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with chronic hepatitis B infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients with 20 years of age and older 2)HB surface antigen positive for over 6 months 3)patients without cirrhosis 4)baseline hemoglobin over 10 g/dl 5)baseline platelet counts over 90000/microL 6)baseline neutrophil over 1500/microL

Exclusion criteria

Exclusion criteria: 1)pregnant woman 2)co-infection with other hepatitis virus (HCV/HDV/HIV) 3)other liver disease such as autoimmune hepatitis, alcoholic liver disease etc. 4)comorbidity with other severe disease or immune dificiency 5)severe depression or other severe mental disease 6)contraindication for interferon treatment

Design outcomes

Primary

Measure	Time frame
probability of HBV DNA negativity decrease rate of HB surface antigen level decrease rate of HB core-related antigen probability of ALT normalization probability of HBe antigen seroconversion cumulative incidence rate of hepatocellular carcinoma	—

Secondary

Measure	Time frame
improvement of liver fibrosis	—

Countries

Japan

Contacts

Public ContactRyoko Yamada

Osaka University Graduate School of Medicine Gastroenterology and Hepatology

ryo726@gh.med.osaka-u.ac.jp81-6-6879-3621

Outcome results